USPTO serial 77178675
ACCRETAMAB
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 14, 2009
- Examiner
- FAHRENKOPF, PAUL
- Law office
- GENERIC WEB UPDATE
What this means
Status 800 means the registration was renewed after acceptable combined Section 8 and Section 9 filings. The mark remains registered for another 10-year term with active federal protection. Calendar the next Section 8 and 9 deadline in 10 years and maintain monitoring.
Need help with ACCRETAMAB?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
TOKYO, JP
CHIYODA-KU, TOKYO, JP
CHIYODA-KU, TOKYO, JP
CHIYODA-KU, TOKYO, JP
Chiyoda-ku Tokyo, JP
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Kaushal R. Odedra
Kaushal R. Odedra ODEDRA LAW OFFICE, PLLC2020 Pennsylvania Ave, NW #152Washington, DC 20006UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | [Host cells for medical or clinical use; cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical or clinical use; transfected cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical or clinical use; pharmaceuticals, namely, central nervous system depressants, preparations for ophthalmic use, anti-histaminics, cardiotonics, arrhythmia treating agents, diuretics, hypotensors, prophylactic for the treatment of asthma, antitussives and expectorants, stomachics and digestives, antacids, hormones, namely, pituitary hormones for the treatment of infertility, thyroid hormones for the treatment of hyperthyroidism, anabolic hormones for the treatment of aplastic anemia and osteoporosis, corticosteroids for treatment of hypopituitarism, congenital adrenal hyperplasia, rheumatoid arthritis, rheumatic fever, crohn's disease, and chronic active hepatitis, estrogen and progesterone used as combined oral contraceptives, urinary antiseptics, analgesics, anti-itching agents, cataplasms for the treatment of bruises, lumbago and stiff shoulder, pharmaceutical preparations used to treat hair disorders, vitamin preparations, food enriching agents for treating vitamin deficiencies, anti-coagulants, enzyme preparations for control of malabsorption and diarrhea, anti-cancer preparations, anti-sarcoma preparations, antibiotics and their preparations for the treatment of infectious diseases, antituberculotic agents, influenza vaccines, diphtheria vaccines, tetanus vaccines, gas gangrene vaccines, Japanese encephalitis vaccines, in vitro tetrodotoxines for medical use, antiprotozoals for the treatment of trichomoniasis and dermatophytosis, anthelmintics for the treatment of threadworm and toxoplasmaosis, naturally occurring drugs for treating peptic ulcers, charred drugs for treating peptic ulcers, moxa for treating peptic ulcers, veterinary drugs for the treatment of distemper in dogs, distomatosis in dogs, coccidian in chickens, and dysentery in pigs, germination controllers and plant rearing agents, namely, herbicides, fungicides, insecticides, bactericides and rodenticides for domestic and or agricultural use, antiseptics, drugs for arteriosclerosis, oncostatic drugs for the treatment for cancer, multienzyme digestants for in vivo use, antifungal antibiotics for treating trichomoniasis and dermatophytosis, anti parkinsonism drugs, minor tranquilizers, and anti anxiety agents, medicinal preparations for the treatment of the central nervous system, the respiratory tract and the cardiovascular system, anti-bacterial preparations, monolithic preparations, medicinal preparations for the treatment of peptic ulcers, anti-inflammatory preparations, analgesic preparations, cephalosporin, cocarboxylase preparations, glutathione preparations, preparations for improving the metabolism and the peripheral circulation, plasma substitutes and extracorporeal circulation flow improvement preparations, diuretic and anti-hypertensive preparations, in vitro diagnostic reagents for medical use, in vitro extra corporeal diagnostic reagents for medical use, in vitro x-ray contrast agents for medical use, in vitro diagnostic media, pharmaceutical preparations for the treatment of insomnia and other sleep related diseases] | SECTION 8 - CANCELLED | — |
| 040 | Contract manufacturing service in the field of antibodies, fragments of antibodies, and derivatives of antibodies; contract manufacturing service in the field of cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; contract manufacturing service in the field of transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; contract manufacturing service in the field of host cells; contract extracting, refining, synthesizing, manufacturing and preparing pharmaceuticals, agricultural chemicals, and chemicals; providing information in the field of manufacturing technology in the field of antibodies, fragments of antibodies, and derivatives of antibodies; technical consultation in the field of manufacturing technology in the field of antibodies, fragments of antibodies, and derivatives of antibodies; providing information in the field of manufacturing technology in the field of cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; technical consultation in the field of manufacturing technology in the field of cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; providing information in the field of manufacturing technology in the field of transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; technical consultation in the field of manufacturing technology in the field of transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; providing information in the field of manufacturing technology in the field of host cells; technical consultation in the field of manufacturing technology in the field of host cells; providing technical information in the field of extracting, refining, synthesizing, manufacturing and preparing pharmaceuticals, agricultural chemicals, and chemicals technical consultation in the field of extracting, refining, synthesizing, manufacturing and preparing pharmaceuticals, agricultural chemicals, and chemicals | ACTIVE | — |
| 042 | Development of new products for others in the field of antibodies, fragments of antibodies, derivatives of antibodies, cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, and host cells; providing technical information in the field of development of new products in the field of antibodies, fragments of antibodies, derivatives of antibodies, cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, and host cells; technical consultation in the field of development of new products in the field of antibodies, fragments of antibodies, derivatives of antibodies, cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, and host cells | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by KYOWA KIRIN CO., LTD.
- Other trademarks owned by KYOWA HAKKO KIRIN CO., LTD.
- Other trademarks owned by KYOWA HAKKO KIRIN CO., LTD.
- Other trademarks owned by KYOWA HAKKO KIRIN CO., LTD.
- Other trademarks owned by KYOWA HAKKO KOGYO CO., LTD.
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named ACCRETAMAB
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 4, 2019 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Apr 10, 2019 | NA89 | NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED | — |
| Apr 10, 2019 | RNL1 | REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS) | The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active. |
| Apr 10, 2019 | 89AG | REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED | The USPTO accepted your combined Section 8 declaration and Section 9 renewal application. The registration is renewed for another 10-year term. The next combined maintenance filing will be due at the following 10-year anniversary. |
| Apr 8, 2019 | E89R | TEAS SECTION 8 & 9 RECEIVED | — |
| Jul 14, 2018 | REM2 | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED | — |
| Aug 5, 2015 | NAS8 | NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED | — |
| Aug 5, 2015 | 8.PR | REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED | — |
| Aug 5, 2015 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jul 1, 2015 | ES8R | TEAS SECTION 8 RECEIVED | — |
| Jul 14, 2009 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 28, 2009 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 8, 2009 | NPUB | NOTICE OF PUBLICATION | — |
| Mar 23, 2009 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Mar 23, 2009 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 24, 2009 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Feb 24, 2009 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 23, 2009 | PAPER RECEIVED | — | |
| Feb 10, 2009 | CNSI | INQUIRY AS TO SUSPENSION MAILED | — |
| Feb 9, 2009 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Feb 9, 2009 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Feb 9, 2009 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 6, 2009 | PAPER RECEIVED | — | |
| Jan 12, 2009 | CNSI | INQUIRY AS TO SUSPENSION MAILED | — |
| Jan 11, 2009 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Dec 11, 2008 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Nov 19, 2008 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Jun 11, 2008 | CNSL | LETTER OF SUSPENSION MAILED | — |
| Jun 11, 2008 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jun 10, 2008 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Jun 10, 2008 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 9, 2008 | PAPER RECEIVED | — | |
| Mar 26, 2008 | CNSI | INQUIRY AS TO SUSPENSION MAILED | — |
| Mar 25, 2008 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Feb 24, 2008 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Feb 24, 2008 | ALIE | ASSIGNED TO LIE | — |
| Aug 24, 2007 | CNSL | LETTER OF SUSPENSION MAILED | — |
| Aug 24, 2007 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Aug 24, 2007 | DOCK | ASSIGNED TO EXAMINER | — |
| May 16, 2007 | NWAP | NEW APPLICATION ENTERED | — |